Platelet-rich plasma (PRP) therapy is widespread in human and animal medicine \[[@r7], [@r13], [@r16], [@r21], [@r28]\]. PRP is easily prepared from autologous whole blood by differential centrifugation and contains concentrated platelets \[[@r5],[@r6],[@r7], [@r25]\]. Therefore, PRP therapy is characterized by immunological safety and cost-effectiveness. Once the platelets are activated, their α-granules release various growth factors, including the transforming growth factor-β (TGF-β) and the platelet-derived growth factor (PDGF) \[[@r7]\]. The efficacy of PRP therapy is believed to be due to the growth factors enhancing tissue regeneration and promoting the healing of lesions \[[@r7]\]. In human medicine, PRP therapy has been developed together with regenerative cell therapy, especially in oral and dental surgery \[[@r10], [@r11], [@r18]\]. In orthopedic surgery, PRP is widely administered for the treatment of disorders including those of tendons, ligaments, bones, joints, and muscles, and favorable results in a clinical context have been reported \[[@r8], [@r21]\]. In equine medicine, PRP therapy is recognized as a technological innovation for the treatment of tendon and ligament injuries. In a study using culture explants, Schnabel *et al*. reported that PRP upregulated collagen gene expression in the superficial digital flexor tendon \[[@r23]\]. Recently, the administration of PRP *in vivo* has also been investigated \[[@r3], [@r27]\].

PRP therapy is now considered to be promising as a novel method of treating skeletal muscle injuries in human athletes \[[@r1], [@r21]\]. Hamid *et al.* reported the results of a randomized controlled trial in which a single autologous PRP injection induced earlier recovery of human acute hamstring injuries \[[@r1]\]. Mei-Dan *et al.* reviewed many case reports describing the effectiveness of PRP injection for human muscle injury \[[@r21]\]. In experimental animal injury models, it was reported that PRP injection promoted muscle regeneration morphologically \[[@r9]\]. Considering these findings, it is also possible that PRP therapy would be useful for muscle injury in equine athletes.

Although many studies on PRP for equine tendon and ligament injuries have been reported, to the best of our knowledge, no detailed reports regarding PRP therapy for equine skeletal muscles have been published. We hypothesized that the expression of genes associated with muscle regeneration would be upregulated and that the activation of satellite cell proliferation would be observed morphologically upon PRP injection, as is the case in injured rats \[[@r6], [@r9]\]. The purpose of this study was thus to investigate the changes in morphology and gene expression that are relevant to skeletal muscles and satellite cells induced by injection of PRP into healthy intact skeletal muscle.

Materials and Methods {#s1}
=====================

Subjects
--------

Seven clinically healthy Thoroughbreds (six males and one female, 6--12 years of age, weighing 435--493 kg) were used in this study. All experimental procedures were reviewed and approved by the Animal Welfare and Ethics Committee of the Equine Research Institute of the Japan Racing Association (authorization number, 2012-9).

Preparation of PRP
------------------

One hundred milliliters of equine whole blood was collected from the jugular vein with a disposable plastic syringe containing 10% sodium citrate anticoagulant (ACD-A injection, Terumo BCT Ltd., Tokyo, Japan). The blood was equally dispensed into 10 polypropylene tubes and then centrifuged at 400 × *g* for 7 min at 4°C. The plasma fraction of each tube was transferred into another polypropylene tube and then centrifuged at 2,000 × *g* for 7 min at 4°C. The supernatant was removed, and the remaining 1 m*l* of PRP in the bottom of each tube was resuspended and collected. The concentration of platelets in the PRP was determined using an automated blood cell counter (Sysmex K-4500, Sysmex Corp., Kobe, Japan). The obtained PRP was stored at −30°C until administered, and a single freeze-thaw cycle was used to induce platelet activation and the release of growth factors \[[@r22], [@r23]\].

Concentrations of PDGF isoform BB (PDGF-BB) and TGF-β isoform 1 (TGF-β1) in the freeze-thawed PRP were determined using ELISA kits (Quantikine Human PDGF-BB ELISA DBB00 and Quantikine Human TGF-β1 ELISA DB100B, R&D Systems, Minneapolis, MN, U.S.A.). These kits were designed for use in samples obtained from humans but have also been validated for use in horses \[[@r3], [@r23], [@r26]\].

Injection of PRP into gluteus medius muscle
-------------------------------------------

All procedures were performed under sedation with medetomidine hydrochloride (Domitor, Nippon Zenyaku Kogyo Co., Ltd., Fukushima, Japan; 5 *µ*g/kg of body weight, IV). Three square patches (2 × 2 cm) on the right gluteus medius muscle were clipped and sterilized. These squares were set 5 cm apart from each other. First, intact muscle samples (PRE) were obtained from one patch by needle biopsy using a SuperCore^TM^ Biopsy Instrument (Argon Medical Devices, Inc., Plano, TX, U.S.A.) under local anesthesia with 2% lidocaine infiltration (Xylocaine, AstraZeneca K.K., Osaka, Japan). Subsequently, 4 m*l* of activated autologous PRP or 4 m*l* of saline was uniformly injected into the muscle at 2 to 3 cm under the skin around the remaining two patches. Five days after the first injection into the right side, the same procedure was performed for the left side symmetrically. At 7 days after the first injection, needle biopsy was performed from all of the injection sites on both sides of the gluteus medius muscle. The muscle samples obtained from the right side were named group *7D* (i.e., 7 days after injection), and those from the left side were named group *2D* (i.e., 2 days after injection). All biopsy samples were frozen quickly using liquid nitrogen and stored at −80°C until analysis. A prophylactic antibiotic (MYCILLIN inj. NZ, Nippon Zenyaku Kogyo Co., Ltd.) was given intramuscularly in the neck, and the wounds were covered with sterile dressings (PRIMAPORE, Smith & Nephew Wound Management K.K., Tokyo, Japan) after biopsy.

Immunohistochemical staining and morphological analysis
-------------------------------------------------------

Serial sections of the biopsy specimens were made and stained according to the immunohistochemical staining method of Kawai *et al.* \[[@r15]\]. Briefly, serial 8 *µ*m cross sections of the muscle were obtained on a cryostat (CM510, Leica Microsystems K.K., Tokyo, Japan) at −20°C and then dried on slides. Immunohistochemical staining was subsequently performed to identify the types of myosin heavy chains (MHCs). A primary monoclonal antibody was applied, namely, either (1) the mouse monoclonal antibody MY-32 (Sigma-Aldrich Japan, Tokyo, Japan), which specifically reacts with MHC-IIa and MHC-IIx; or (2) the mouse monoclonal antibody SC-71 (DSHB, Iowa City, IA, U.S.A.), which specifically reacts with MHC-IIa, followed by a reaction with a secondary antibody (goat anti-mouse IgG) conjugated with horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA, U.S.A.). Diaminobenzidine tetrahydrochloride (DAB) was used as a chromogen.

To identify satellite cells, immunofluorescent staining was performed on another serial section from each biopsy, fixed in 4% paraformaldehyde. The primary monoclonal antibodies \[a mouse anti-Pax7 (DSHB) and a rabbit anti-laminin L9393 (Sigma-Aldrich Co. LLC, St. Louis, MO, U.S.A.)\] were applied, followed by the application of secondary antibodies: Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Inc., West Grove, PA, U.S.A.) and Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes, Tokyo, Japan), respectively. Cell nuclei were counterstained with DAPI.

Images of the stained muscle fibers were recorded with a photomicroscopic image-processing system (ACT-2U, Nikon, Tokyo, Japan). The fibers were classified as type I \[MY-32 (−), SC-71 (−)\], IIa \[MY-32 (+), SC-71 (+)\], or IIx \[MY-32 (+), SC-71 (−)\], and the fiber-type component ratio was determined according to Yamano *et al.* \[[@r29]\].

The images of the distributions of anti-Pax7, anti-laminin, and cell nuclei were merged using image processing software (Photoshop, Adobe Systems Inc., San Jose, CA, U.S.A.) and used for the identification of satellite cells. The cells positive for both DAPI and Pax7 at the periphery of each fiber beneath the basal lamina stained with the anti-laminin were identified as satellite cells \[[@r15]\].

Thereafter, about 25 fibers of type I and 50 fibers of type IIa and type IIx were randomly chosen, the numbers of myonuclei and satellite cells were counted, and the cross-sectional area of myofibers was then measured for each different type of fiber using the ImageJ software (NIH, Bethesda, MD, U.S.A.), followed by calculation of the mean number of myonuclei per fiber, the central nuclear ratio, the mean myonuclear domain size, and the mean number of satellite cells per fiber.

Real-time RT-PCR
----------------

Each muscle sample was analyzed for the expression of several mRNAs using a real-time RT-PCR system, in accordance with the method of Kawai *et al.* \[[@r15]\]. Total RNA was extracted using a TRIzol reagent (Invitrogen, Tokyo, Japan). The purity and yields of total RNA were determined by measuring the absorbance of the aliquots at 260 and 280 nm. Total RNA was then treated for 30 min at 37°C with TURBO DNase (Ambion, Tokyo, Japan) to remove genomic DNA from samples. DNase-treated RNA (0.5 *µ*g) was used to synthesize first-strand cDNA with an Exscript^TM^ RT Reagent Kit (Takara, Shiga, Japan). Thereafter, the cDNA products were analyzed by real-time PCR using the SYBR Green PCR Master Mix protocol in a StepOne Real Time PCR System (Applied Biosystems Japan, Tokyo, Japan).

The amplification program included an initial denaturation step at 95°C for 10 min, and then 40 cycles of denaturation at 95°C for 30 sec and annealing/extension at 58°C for 1 min. The amount of *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) mRNA was estimated as an internal control. Each mRNA was normalized to *GAPDH* by subtracting the cycle threshold (Ct) value of *GAPDH* from the Ct value of the gene target. The relative expression of the target gene was calculated as the relative quantification (RQ) value for the PRE value. After determining the relative expression, dissociation-curve analysis detected no nonspecific amplification in cDNA samples.

Gene expression was analyzed, including for *MHC-I, MHC-II, embryonic* (i.e., undifferentiated) *MHC* (*MHC-e*)*, creatine kinase* (*CK*)*, Pax7, myogenic determination factor* (*MyoD*)*, myogenin, interleukin-6* (*IL-6*)*, insulin-like growth factor isoform 1* (*IGF-1*)*, and hepatocyte growth factor* (*HGF*)*.* The sequences of the specific primers used in this experiment are listed in the Appendix [Table A1](#tbl_0A1){ref-type="table"}Table A1.Real-time RT-PCR primer sequences used in the studyGAPDHFCAAGGCTGTGGGCAAGGTRGGAAGGCCATGCCAGTGAMHC-IFGGAATGACAACTCCTCTCGCTTTRTCAATATCAGCAGAAGCCAGTTTCMHC-IIFCCCATGAACCCTCCCAAATARGCAGGCTCATGCAGGTGAGTMHC-eFTCACTTTGTGCGCTGTATAATTCCRCTGGTGCAGGACAAGGCTATGCKFGGAATCAGCGCCGGAAARACCAATAGCACCCCCTGTCAPax7FCATCGGCGGCAGCAARTCCTCGATCTTTTTCTCCACATCMyoDFACGGCTCTCTCTGCAACTTTGRGAGTCGAAACACGGGTCATCAMyogeninFTCACGGCTGACCCTACAGATGRGGTGATGCTGTCCACAATGGIL-6FAACAACTCACCTCATCCTTCGAARCGAACAGCTCTCAGGCTGAACIGF-1FTGTCCTCCTCACATCTCTTCTACCTRCGTGGCAGAGCTGGTGAAHGFFGGTACGCTACGAAGTCTGTGACARCCCATTGCAGGTCATGCAT. Each PCR primer was designed using Primer Express software v3.0 (Kanagawa, Japan), and the oligonucleotides were purchased from FASMAC Co., Ltd. (Kanagawa, Japan).

Statistical analysis
--------------------

The data obtained from the histochemical analysis were compared using one-way ANOVA. To compare the mRNA expression of each target gene between the groups injected with saline and those injected with PRP, the Wilcoxon signed-rank test was used. Analyses were performed using Microsoft Excel 2007 Macro applications (Statcel3, OMS Publishing Inc., Saitama, Japan). Statistical significance was set at *P*\<0.05.

Results {#s2}
=======

PRP
---

The number of platelets collected from the seven horses ranged from 5.4 to 13.3 × 10^4^/*µl* (mean ± SD, 9.8 ± 2.8 × 10^4^/*µl*) in whole blood, and from 62.6 to 85.0 × 10^4^/*µl* (72.3 ± 8.2 × 10^4^/*µl*) in PRP. The concentration of platelets in PRP ranged from 5.4 to 12.1 times (7.9 ± 2.3 times) higher than that in whole blood. The freeze-thawed PRP contained 5.0 ± 1.6 ng/m*l* PDGF-BB and 15.4 ± 6.6 ng/m*l* TGF-β1. The concentrations of PDGF-BB and TGF-β1 in PRP were 5.0 ± 0.7 times and 3.7 ± 1.7 times higher than those in serum, respectively. There was no correlation among the concentrations of platelets, PDGF-BB, and TGF-β1 in PRP.

Morphological analysis of muscle
--------------------------------

Typical images of immunohistochemical and immunofluorescent staining are shown in [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Typical merged images of triple-immunofluorescent staining for laminin (green), Pax7 (red), and nuclei (blue) before PRP or saline injection and at 2 and 7 days after it. All images contain some satellite cells (white arrow) and central nuclei (white circle). 2D, 2 days after injection, and 7D, 7 days after injection. Scale bar=100 *µ*m.. The results of morphological measurements of muscle are shown in [Table 1](#tbl_001){ref-type="table"}Table 1.The morphological measurements of the muscle samplesType IType IIaType IIxFiber-type component ratio (%)2DPRE12.8 ± 4.147.7 ± 4.639.5 ± 5.4Saline10.0 ± 3.949.0 ± 5.441.0 ± 8.3PRP11.9 ± 2.746.4 ± 7.441.7 ± 8.57DPRE11.7 ± 5.346.5 ± 5.241.8 ± 7.7Saline12.1 ± 3.047.9 ± 6.340.0 ± 7.5PRP11.9 ± 3.344.6 ± 4.043.5 ± 6.5Cross-sectional area of fibers (×10^3^*µ*m^2^)2DPRE2.61 ± 0.803.25 ± 0.504.22 ± 0.45Saline2.66 ± 0.833.18 ± 0.463.75 ± 0.43PRP2.61 ± 1.043.15 ± 1.153.85 ± 0.937DPRE2.38 ± 0.773.10 ± 0.554.06 ± 0.78Saline2.86 ± 0.813.06 ± 0.763.76 ± 1.01PRP2.69 ± 0.792.92 ± 0.583.97 ± 0.90Myonuclei/fiber2DPRE2.63 ± 0.412.83 ± 0.422.92 ± 0.35Saline3.06 ± 0.452.87 ± 0.482.85 ± 0.30PRP2.83 ± 0.433.11 ± 0.553.02 ± 0.477DPRE2.91 ± 0.353.00 ± 0.323.18 ± 0.33Saline3.00 ± 0.493.13 ± 0.553.05 ± 0.61PRP3.14 ± 0.383.12 ± 0.373.20 ± 0.40Central nuclear ratio (%)2DPRE4.00 ± 6.114.57 ± 7.097.42 ± 8.46Saline1.71 ± 4.532.57 ± 2.769.71 ± 11.10PRP0.57 ± 1.511.71 ± 1.804.57 ± 2.237DPRE001.00 ± 2.00Saline3.42 ± 6.295.42 ± 6.808.29 ± 6.68PRP1.14 ± 1.954.00 ± 4.478.57 ± 10.11Mean myonuclear domain (×10^3^*µ*m^2^)2DPRE1.14 ± 0.411.23 ± 0.361.60 ± 0.35Saline0.93 ± 0.281.19 ± 0.281.50 ± 0.28PRP0.98 ± 0.351.07 ± 0.261.39 ± 0.287DPRE0.89 ± 0.281.13 ± 0.211.45 ± 0.36Saline1.00 ± 0.141.06 ± 0.191.36 ± 0.35PRP0.91 ± 0.251.04 ± 0.261.36 ± 0.25Mean number of satellite cells/fiber (×10^−1^)2DPRE2.91 ± 1.843.86 ± 1.933.34 ± 2.09Saline3.63 ± 1.813.40 ± 1.333.49 ± 1.54PRP3.74 ± 1.543.74 ± 1.463.20 ± 1.977DPRE2.10 ± 0.603.25 ± 1.352.70 ± 0.35Saline3.23 ± 1.933.74 ± 1.683.17 ± 1.53PRP3.14 ± 1.953.87 ± 1.003.57 ± 1.00There were no significant differences among the treatments (PRE, saline, and PRP) within the same type of myofiber and same number of days after injection (2D, 2 days after injection, and 7D, 7 days after injection; mean ± SD).. There were no obvious morphological findings or significant differences among the PRE, saline, and PRP injection groups within the same type of myofiber and the same number of days after injection.

Real-time RT-PCR
----------------

At 2 days after intramuscular injection, *MHC-e* gene expression was significantly higher in the case of treatment with PRP (mean ± SE, 4.09 ± 1.54) compared with treatment with saline (1.20 ± 0.18) ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.The mRNA expression of the skeletal muscle samples obtained 2 days after intramuscular injection (n=7; mean ± SE; logarithmic scale). The value of the target gene is calculated as the relative quantification (RQ) value for the PRE value set at 1.00. The *MHC-e* expression level in the case of treatment with PRP was significantly higher than that in the case of treatment with saline (\**P*\<0.05). *Myo*=*myogenin*.). At 7 days after intramuscular injection, *MHC-I* gene expression was significantly higher in the case of treatment with PRP (1.78 ± 0.26) compared with treatment with saline (1.33 ± 0.22) ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.The mRNA expression of the skeletal muscle samples obtained 7 days after intramuscular injection (n=7; mean ± SE; logarithmic scale). The value of the target gene is calculated as the relative quantification (RQ) value for the PRE value set at 1.00. *MHC-I* and *HGF* expression levels in the case of treatment with PRP were significantly higher than those in the case of treatment with saline (\**P*\<0.05). *Myo*=*myogenin*.).

At 7 days, *CK, Pax7, MyoD*, and *myogenin* expression did not differ significantly between saline and PRP injection, although their levels were low at 2 days after the injection of either PRP or saline ([Figs. 2](#fig_002){ref-type="fig"} and[3](#fig_003){ref-type="fig"}). The expression levels of other genes, namely, *IL-6*, *IGF-1*, and *HGF*, were similar at 2 and 7 days after injection of either PRP or saline ([Figs. 2](#fig_002){ref-type="fig"} and[3](#fig_003){ref-type="fig"}). A significant difference in the expression of *HGF* was detected upon comparison of PRP (2.91 ± 1.03) and saline (1.58 ± 0.29) at 7 days after injection ([Fig. 3](#fig_003){ref-type="fig"}).

Discussion {#s3}
==========

Human studies have indicated that a therapeutic dose of platelets in PRP is approximately 1.0 × 10^6^/*µl*, which is four to five times higher than the level in whole blood \[[@r7], [@r19]\]. Although the appropriate dose of platelets in PRP for equine practice remains unclear, the number of platelets and the growth factor concentrations of the PRP used in this study were similar to those in previous studies \[[@r23], [@r25]\]; therefore, we concluded that an effective level of PRP was administered in this study.

In the injured human muscle, satellite cell proliferation peaks at days 2--3 following injury, and significant numbers of centronucleated myofibers are observed at days 5--7 \[[@r24]\]. In our study, however, there was no difference in the histological findings among the three groups regardless of sampling time. In rodent injury models, Hammond *et al.* reported that PRP promoted muscle regeneration functionally and histologically \[[@r9]\]. By contrast, Delos *et al*. \[[@r5]\] reported that there was no difference functionally or morphologically between saline and PRP injection. In both reports, a common view was expressed that PRP may be of greater utility in treating multiple repetition injury, which relies on a muscle regeneration mechanism associated with satellite cell activity, rather than in treating a single contusion, which predominantly causes sarcolemmal injury. In our study, PRP was not injected into sites with severe injury, such as multiple repetition injury, but was instead injected into intact healthy muscle. Thus, the fact that no proliferation was observed in satellite cells and myofibers induced by PRP injection seems to be consistent with these suggestions.

Hammond *et al.* reported that PRP enhanced the expression of *MyoD* and *myogenin* genes in rodent injury models \[[@r9]\]. In this study, however, the same expression levels of marker genes related to myogenic satellite cell proliferation and differentiation, including *Pax7*, *MyoD*, *myogenin*, and *CK* \[[@r12], [@r14]\], were observed in both the PRP and saline groups at 7 days after injection. Our results were insufficient to prove that PRP upregulated satellite cell activity.

Injury causes the activation of inflammatory cells, and these cells release multiple cytokines including IL-6 \[[@r4], [@r30]\]. It is also known that IL-6 works as an activator of STAT3 protein, which activates satellite cells \[[@r14], [@r30]\]. In our study, the expression of the *IL-6* gene was detected in muscle samples obtained around the injection sites despite using intact muscle. On comparing the PRP and saline injection groups, higher expression tended to be observed in the PRP group. However, no significant difference was observed at either sampling time points because of large standard errors. Dimauro *et al.* reported that PRP could not induce upregulation of the expression of the *IL-6* gene by using a rat muscle injury model \[[@r6]\]. Our results support their finding despite the fact that we used intact muscle. These findings may suggest that the effect of PRP on the expression of the *IL-6* gene could considerably vary between individuals. PRP injected into intact muscle seemed to have no apparent effect on satellite cell activity compared with saline injection.

Additionally, although the expression of growth factor genes such as *HGF* and *IGF-1* was detected in the 2D and 7D samples, there was no significant difference in the expression of these genes between the PRP and saline injections, except that the expression of *HGF* in the PRP group was significantly higher than that in the saline group in the 7D sample. HGF and IGF-1 are known to be stored within the α-granules of platelets \[[@r3], [@r20], [@r23]\] and to promote skeletal muscle regeneration \[[@r14], [@r24]\]. It is also known that activated platelets induce the coagulation cascade and platelet degranulation with the release of various growth factors upon bleeding injury \[[@r2], [@r7]\]. If considerable bleeding was caused by the PRP or saline injection itself, it would be likely that activated platelets could release growth factors, including HGF and IGF-1, and equally upregulate the expression of these genes around the injection sites via a paracrine mechanism, regardless of the injected solution \[[@r2], [@r19]\]. Irrespective of this, no additional effect of PRP was observed in this study. Although the reason for the significantly higher expression of *HGF* in the PRP group in the 7D sample remains unclear, our results suggest that PRP has no effect on growth factor activity, as well as satellite cell activity and *IL-6* expression.

Meanwhile, we detected significantly higher levels of *MHC-e* expression 2 days after PRP injection and significantly higher levels of *MHC-I* expression 7 days after PRP injection compared with the equivalent periods after saline injection. A number of studies have reported positive effects of PRP on myogenic proliferation and differentiation \[[@r6], [@r9], [@r21]\]. The elevation of the expression of *MHC-e* and *MHC-I* genes in this study might have been caused by satellite cell activation induced by PRP because activated satellite cells are essential for regenerating MHC \[[@r14], [@r17]\]. However, it was unclear why PRP injection had no significant effect on the expression of genes related to satellite cell activity, including *Pax7*, *MyoD*, *myogenin*, and *CK*. It is also necessary to mention that this preliminary study using intact muscle had a limitation in that the mechanism by which gene expression was influenced by the PRP or saline injection itself was not determined.

In summary, it is suggested that injection of PRP into intact skeletal muscle does not induce specific morphological changes, but upregulates the expression of genes related to muscle regeneration. Further studies such as on the administration of PRP into an experimentally induced severe wound in skeletal muscle without considerable bleeding would be needed to clarify the effects of PRP injection on muscle regeneration or repair.
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